{"symbol":"AMGN","fiscalQuarter":"Q2-2026","reportDate":"2026-08-04","reportTime":"AMC","status":"upcoming","company":{"name":"Amgen Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/AMGN/earnings/Q2-2026","preBrief":{"companySnapshot":"Amgen Inc. is a biotechnology company that develops and manufactures innovative therapies for serious illnesses. Operating in the Health Care sector, Amgen focuses on areas such as oncology, cardiovascular disease, and inflammation, making its products vital in improving patient outcomes.","keyMetrics":[{"name":"Earnings Per Share (EPS)","why":"EPS is a key indicator of profitability and will show how well Amgen is managing its costs and revenue.","consensus":"N/A"},{"name":"Revenue Growth","why":"Revenue growth indicates the company's ability to expand its market presence and is crucial for assessing overall business health.","consensus":"N/A"}],"lastQuarterRecap":{"summary":"In Q1-2026, Amgen reported an EPS of $5.15, exceeding analyst expectations by 8.88%. The stock reacted positively, gaining 2.43% the following day.","promises":[]},"wallStreetExpectations":{"summary":"Investors are cautiously optimistic ahead of Amgen's Q2-2026 earnings report, especially given its history of beating EPS estimates. However, there is uncertainty regarding revenue growth and overall market conditions.","bullCase":"If Amgen continues its trend of beating EPS estimates, it could signal strong operational performance and investor confidence, potentially driving the stock higher.","bearCase":"Conversely, if Amgen fails to meet expectations or provides weak guidance, it could lead to a sell-off, especially given the current market volatility."},"optionsSignal":{"impliedMove":"3.48%","context":"The options market is pricing in a move of about 3.5%, suggesting that traders expect some volatility around the earnings announcement."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+8.88%","reaction":"+2.43%"},{"quarter":"Q4-2025","epsSurprise":"+11.18%","reaction":"-1.77%"},{"quarter":"Q3-2025","epsSurprise":"+12.75%","reaction":"+0.13%"},{"quarter":"Q2-2025","epsSurprise":"+15.61%","reaction":"-0.62%"},{"quarter":"Q1-2025","epsSurprise":"+17.85%","reaction":"-2.45%"}],"pivotalQuestions":[{"question":"What will the EPS be for Q2-2026, and how does it compare to previous quarters?","whyItMatters":"Given Amgen's strong track record of beating EPS estimates, this will be a crucial indicator of its ongoing financial health."},{"question":"What guidance will management provide for revenue growth in the upcoming quarters?","whyItMatters":"Revenue growth is essential for assessing the company's future prospects, and any guidance will heavily influence investor sentiment."}],"thesisBreakLevels":{"bullTrigger":"An EPS of $5.50 or higher would confirm the bull case and suggest strong operational performance.","bearTrigger":"An EPS below $4.80 would confirm the bear case, indicating potential issues with profitability.","context":"The market is currently weighing Amgen's ability to maintain its earnings momentum against potential revenue challenges."},"scenarioPlaybook":{"beatAndRaise":"If Amgen beats expectations, history suggests the stock could rise by around 1.09% on the first day, confirming positive momentum.","inLineCautious":"If results are in line with expectations, the stock may experience muted movement as investors digest the details.","miss":"A miss could lead to a decline, with historical patterns indicating a potential drop of around 2.45%."},"peerReadThroughs":[],"setupPatternInsight":{"pattern":"Prior-quarter beat + options rich in Health Care","sampleSize":30,"fadeRate":"13 of 29 (45%)","insight":"This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held \u2014 no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias)."},"whatTheStreetIsMissing":{"thesis":"The Street may be underestimating Amgen's ability to sustain its earnings growth despite potential revenue challenges, as historical performance indicates resilience.","supportingPoints":["Amgen has consistently beaten EPS estimates, suggesting strong operational management.","The options market is pricing a larger move than historical averages, indicating potential for a significant reaction.","Insider trading activity shows mixed signals, which could indicate uncertainty among insiders about future performance."],"riskToConsensus":"If Amgen's EPS comes in below $5.00, it could challenge the current positive sentiment."},"whatToListenFor":["Any updates on new product launches or pipeline developments.","Management's commentary on market conditions and competitive landscape.","Insights into cost management strategies and their impact on margins.","Details on international sales performance and growth opportunities.","Any changes to the long-term strategic vision or goals."],"metaDescription":"Amgen (AMGN) reports Q2 2026 earnings August 4. Investors are watching for EPS performance and revenue guidance."}}